News

Researchers at the University of Colorado Boulder and Tsinghua University in China recently published in the journal Science Advances that a specific small molecule is capable of triggering an immune response, having potential biomedical applications for treating diseases such as Scleroderma. The study is entitled “…

In a new study entitled “Subclinical atherosclerosis and peripheral vascular disease in systemic sclerosis patients: Relation to potential risk factors,” authors suggest that patients with Systemic sclerosis may have increased risk of developing subclinical atherosclerotic macro vascular disease. The team highlights that further research is necessary to tackle both…

The European Commission has granted late stage cell therapy company Cytori Therapeutics, Inc.’s ECCS-50 cellular therapy the designation of orphan medicinal product for the treatment of scleroderma. The decision, which was made due to positive references from the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products, represents the first time an…

A study recently published in the on-line journal Clinical and Experimental Rheumatology is challenging the clinical assumptions that morphea and systemic sclerosis (SSc) should be considered the part of the same disease spectrum.  The study, entitled, “Prospective evaluation of frequency of signs of systemic sclerosis…

Researchers from the University of Cologne in Germany showed that Systemic sclerosis-overlap Syndrome should be regarded as different separate subset in Systemic sclerosis (SSc) patients. The study entitled “Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis” appeared on…